1. Brain JD, Blanchard JD. Mechanisms of particle deposition and clearance. In: Morén F, Dolovich MB, Newhouse MT, Newman SP, eds.Aerosols in Medicine. New York, NY: Elsevier; 1993:117–156.
2. Gonda I. Targeting by deposition. In: Hickey AJ, ed.Pharmaceutical Inhalation Aerosol Technology. New York, NY: Marcel Dekker; 1992:61–82.
3. Hinds WC.Aerosol Technology. New York, NY: John Wiley & Sons: 1999:233–259.
4. FDA. CDER. Draft guidance for industry: bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action. 1999; Available at: http://www.fda.gov/cder/guidance/2070DFT. pdf. Accessed April 17, 2006.
5. FDA. CDER. Draft guidance for industry: metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products—chemistry, manufacturing, and controls documentation. 1998; Available at: http://www.fda.gov/cder/guidance/2180dft.pdf. Accessed April 17, 2006.